{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Meeske AJ"],"funding":["Howard Hughes Medical Institute","Burroughs Wellcome Fund","NIH Office of the Director","National Cancer Institute","NCI NIH HHS","National Institute of General Medical Sciences","NIGMS NIH HHS"],"pagination":["54-59"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7975689"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["369(6499)"],"pubmed_abstract":["The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of <i>Listeria seeligeri</i> Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of Acr"],"journal":["Science (New York, N.Y.)"],"pubmed_title":["A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity."],"pmcid":["PMC7975689"],"funding_grant_id":["1DP1GM128184-01","GM129430","P30 CA008748","P30CA008748","DP1 GM128184","R01 GM129430","PATH Award"],"pubmed_authors":["Cassel AK","Kozlova A","Liao J","Patel DJ","Jia N","Wiedmann M","Meeske AJ","Marraffini LA"],"additional_accession":[]},"is_claimable":false,"name":"A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity.","description":"The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of <i>Listeria seeligeri</i> Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of Acr","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Jul","modification":"2026-05-09T09:50:42.95Z","creation":"2025-04-06T13:15:38.833Z"},"accession":"S-EPMC7975689","cross_references":{"pubmed":["32467331"],"doi":["10.1126/science.abb6151"]}}